Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 15/20 | 0.48 |
| ▸ | DRD2 | P14416 | 9/20 | 0.44 |
| ▸ | DRD3 | P35462 | 6/20 | 0.44 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16271965 | 0.86 | DRD4 (0.52) | DRD4DRD2DRD3PDCD1LG2CD274 | |
| SCHEMBL16271995 | 0.84 | DRD4 (0.52) | DRD4DRD2DRD3PDCD1LG2CD274 | |
| SCHEMBL17721305 | 0.81 | PDCD1LG2 (0.43) | PDCD1LG2CD274OPRM1OPRK1OPRL1 | |
| SCHEMBL16271979 | 0.81 | DRD4 (0.48) | DRD4DRD2DRD3PDCD1LG2CD274 | |
| SCHEMBL17677207 | 0.78 | DRD4 (0.53) | DRD4DRD2DRD3ADRA1DADRA1A | |
| SCHEMBL17721304 | 0.75 | DRD4 (0.55) | DRD4DRD2DRD3 | |
| SCHEMBL17677194 | 0.73 | DRD4 (0.48) | DRD4DRD2DRD3PDCD1LG2CD274 | |
| SCHEMBL17721303 | 0.73 | DRD4 (0.50) | DRD4DRD2DRD3PDCD1LG2CD274 | |
| SCHEMBL6195713 | 0.71 | DRD4 (0.59) | DRD4DRD2DRD3 | |
| SCHEMBL16272070 | 0.71 | DRD4 (0.48) | DRD4DRD2DRD3PDCD1LG2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732065-B2 | Cyclic aminomethyl pyrimidine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-9732065-B2 | Cyclic aminomethyl pyrimidine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-05 | — | — | US | disclosed |
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-05 | — | — | US | disclosed |
| EP-3006438-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2016-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | DRD2, DRD4, DRD1 | DRD4 2/4885DRD2 1/4885DRD3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.